All News

Dr. Jordan Dimitrakov discusses the use of memantine in chronic pelvic pain syndrome with Urology Times.

Dr. Williams and Dr. Nangia discuss the effects of cardiometabolic disorders in aging men.

Despite bringing lower rates of positive surgical margins and lower PSA nadirs, long-term neoadjuvant hormonal therapy did not lead to a difference in rates of PSA recurrence after 7 years.

Different areas of the brain are active in different chronic pain conditions, and now researchers have shown that those areas are distinctly different in patients with interstitial cystitis and chronic prostatitis/chronic pelvic pain syndrome.

Urologists from around the country give their opinions on health care reform.

Brachytherapy and radical prostatectomy are effective treatments for localized prostate cancer, but have different long-term functional effects, 13-year follow-up data show.

BPH and lower urinary tract symptoms are very common, increase as a function of age, and are often managed through watchful waiting.

Androgen deprivation therapy leads to an increased risk of bone fractures and other side effects of estrogen deficiency in men with prostate cancer, but those effects can be successfully treated with the use of an oral selective estrogen receptor modulator, suggest the results of a large, prospective, randomized tria presented at the AUA annual meeting in Chicago.

During our working years, we justify the negative impact of inflation by relying on the expectation that our incomes will rise at levels consistent with or above inflation. Unfortunately, many of today's physicians are experiencing just the opposite.

Twice-yearly injections of denosumab improved bone mineral density in men with prostate cancer treated with androgen deprivation therapy.

Discovery of the prostate carcinoma-specific gene has led to the development of a promising urine-based laboratory test for the disease.

In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting.

Two of several studies presented by the same international team suggest that high-intensity focused ultrasound provides good biochemical-free survival at 5 years in patients treated in the absence of hormone therapy.

A single session of high-intensity focused ultrasound as primary therapy for localized prostate cancer results in an acceptable rate of biochemical-free recurrence.

Laparoscopic radical prostatectomy has a definite learning curve, but it is slower than the learning curve for open surgery and is worsened in surgeons with prior open training.

Studies show that employee theft robs small business owners, which includes physicians, of $20 to $40 billion annually.

Men with CP/CPPS who responded to treatment in two trials reported better quality of life, particularly physical quality of life, and better sexual functioning.

Urologists plan on complying with new rules, but some see it as 'overkill.'

Due to PSA screening practices in the U.S., three-fourths of American men with prostate cancer may be eligible for focal ablation.

As research reveals more associations between cardiometabolic disorders and urologic disease, experts are emphasizing the importance of the urologist in detecting cardiometabolic risk factors in patients.

A new computerized tool may solve the problem of the time and effort it takes to have patients fill out forms to assess quality of life.

Two large studies of cryoablation for prostate cancer showed positive disease-free rates.

Recent research suggests similarities in the etiologic and pathogenetic mechanisms of chronic pelvic pain syndrome and other pain syndromes.

With a tight economy making patients more reluctant to seek medical care, marketing becomes appealing for even stable practices to have a good foothold in the community.

The definition of "consult" has moved the target for reimbursement over the years.

Light-activated drug therapy for BPH has been shown to be safe and painless in a phase I/II trial.

A look at new products and services from Karl Storz Endoscopy-America, Eloquest Healthcare, Abbott Laboratories, and Spectrum Surgical.

Urologists are in a unique position to detect cardiometabolic risk factors at an early stage and intervene.

PSA velocity and PSA doubling time, once considered promising tools for identifying the need for intervention in prostate cancer patients under active surveillance, now appear to have failed to meet that promise.

Permanent brachytherapy's long-term success depends on delivery of a high biological effective dose of radiation.